Skip to main content
Premium Trial:

Request an Annual Quote

GMU Proteomics Partners with Virginia Clinic on Myeloma Study

NEW YORK (GenomeWeb News) – Cancer and proteomics scientists at George Mason University have created a partnership with Fairfax-Northern Virginia Hematology Oncology in a privately-funded program aimed at finding the protein signal pathways involved in multiple myeloma.
The University’s Center for Applied Proteomics and Molecular Medicine will use funding from the Chris Walker Multiple Myeloma Foundation to work with the Fairfax clinic to study the effects of experimental treatments on living tumor cells from multiple myeloma patients.
The goal is to try to use the pathways analysis to develop novel therapeutic targets for treatments of a blood cancer that, according to the Multiple Myeloma Research Foundation, will be diagnosed in nearly 20,000 people in 2008. 
"This novel trial will test a large series of targeted inhibitors, alone and in unique combinations, which block key signaling pathways in the tumor cells,” CAPMM Co-director Lance Liotta said in a statement. “This is a key first step toward true individualized therapy for multiple myeloma."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.